Strides Shasun receives CCI nod for acquisition of two CNS division of Ranbaxy

Strides Shasun has received order on January 21, 2016 under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transaction of the company for acquisition of Ranbaxy’s two CNS divisions. With this approval, all necessary regulatory approvals have been obtained.

Last year in September, the company was in process of acquiring Ranbaxy’s two divisions in Central Nervous System (CNS) segment in India from Sun Pharmaceutical Industries for Rs 165 crore. The pharma major and Sun Pharma had entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.